Allist
Shanghai-based innovative oncology pharmaceutical company focused on first-in-class and best-in-class cancer drugs, listed on the SSE STAR Market.
Last updated September 28, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Allist (艾力斯) is a Chinese innovative pharmaceutical company headquartered in the Zhoupu Medical Park in Pudong, Shanghai. Founded in March 2004 by entrepreneur Du Jinhao and Dr. Guo Jianhui, a scientist honored with the U.S. National Institutes of Health (NIH) Lifetime Scientist distinction, Allist integrates research and development, manufacturing, and marketing. The company positions itself as an innovation-driven biopharmaceutical enterprise dedicated to oncology, pursuing first-in-class and best-in-class drugs with independent intellectual property rights that are safe, effective, and broadly accessible. Allist's core therapeutic focus is oncology, particularly non-small cell lung cancer (NSCLC). Its flagship product is 艾弗沙® (furmonertinib mesylate tablets), a third-generation EGFR inhibitor approved in China. Furmonertinib was approved by China's National Medical Products Administration (NMPA) in 2021 as Allist's second Class 1 new drug, and it entered China's National Reimbursement Drug List (NRDL) in 2021. A first-line indication for EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive locally advanced or metastatic NSCLC was approved in 2022 and entered the NRDL in 2023. The company also markets 艾瑞凯® (glecirasib citrate tablets) and holds exclusive promotion rights in mainland China for 普吉华® (pralsetinib capsules). Allist completed A-round and A+ round financing in 2019, completed its shareholding reform to become Shanghai Allist Pharmaceuticals Co., Ltd., and listed on the Shanghai Stock Exchange STAR Market on December 2, 2020 under stock code 688578. The company operates a research center in Zhoupu Medical Park, a marketing subsidiary (Shanghai Allist Marketing Planning Co., Ltd., founded 2019), and a manufacturing base through Jiangsu Allist Biomedical Co., Ltd. (founded September 2009, registered capital RMB 240 million, located in Qidong, Jiangsu, covering 74,000 square meters). Allist has built a commercialization network with a marketing team of over 950 people covering 31 provinces, autonomous regions, and municipalities in China. Allist pursues both independent R&D and external partnerships, including out-licensing furmonertinib overseas to ArriVent and collaborating with Belgium's OCTIMET Oncology. Its pipeline includes preclinical programs targeting RET, KRAS G12C, KRAS G12D, SOS1, and fourth-generation EGFR inhibitors for C797S resistance mutations. The company has been recognized as a high-tech enterprise and among China's top 100 pharmaceutical innovation enterprises.
History
Allist was founded in March 2004 in Shanghai by entrepreneur Du Jinhao and Dr. Guo Jianhui, a scientist with the U.S. National Institutes of Health (NIH) Lifetime Scientist honor. The company was established as an innovative pharmaceutical enterprise integrating R&D, manufacturing, and marketing, with a mission to address unmet clinical needs in oncology through first-in-class and best-in-class drugs. In 2007, China's National Medical Products Administration (NMPA) approved the clinical trial application for allisartan, an antihypertensive drug candidate. In 2008, Allist expanded its R&D center, and the allisartan clinical study was designated a major project under the Ministry of Science and Technology's 863 Program for major diseases in modern medicine. In 2009, the company launched a proton pump inhibitor (lansoprazole enteric-coated pellet capsules), and Jiangsu Allist Biomedical Co., Ltd. was established as an industrialization base. In 2010, Jiangsu Allist was formally founded with registered capital of RMB 240 million, and allisartan was successfully included in the National Major New Drug Innovation Program's 11th Five-Year Plan. In 2012, the NMPA approved the marketing application for allisartan, making it China's first Class 1 antihypertensive sartan drug. In 2013, Allist transferred allisartan to Shenzhen Salubris Pharmaceuticals. The company was recognized as a high-tech enterprise and passed re-certification in 2016. In 2016, the NMPA approved the clinical trial application for furmonertinib. In 2019, Allist completed A-round and A+ round financing, completed its shareholding reform to become Shanghai Allist Pharmaceuticals Co., Ltd., established Shanghai Allist Marketing Planning Co., Ltd., had furmonertinib included in the NMPA's priority review list, and broke ground on its headquarters R&D base in the International Medical Park. In 2020, Allist partnered with Belgium's OCTIMET Oncology for combination therapy with furmonertinib, and on December 2, 2020, listed on the Shanghai Stock Exchange STAR Market (stock code 688578). The company was named among China's Top 100 Pharmaceutical Innovation Enterprises in 2020. In 2021, the NMPA approved the marketing application for 艾弗沙® (furmonertinib mesylate), Allist's second Class 1 new drug. 艾弗沙® entered China's National Reimbursement Drug List (NRDL) in 2021. Allist also entered an exclusive overseas licensing agreement for furmonertinib with ArriVent and signed a technology transfer agreement with Fudan University for the PGAM1 inhibitor KH3 project. In 2022, 艾弗沙® received the "2021 Drug Innovation Jishi Award — Annual Drug Innovation Achievement Award," and its first-line indication was approved for EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive locally advanced or metastatic NSCLC. In 2023, the first-line indication of 艾弗沙® entered the NRDL. Allist has continued to expand its pipeline and partnerships, including licensing in a potential global first-in-class ADC in 2026 and advancing furmonertinib into adjuvant treatment for EGFR-mutant NSCLC. The company operates a research center in Zhoupu Medical Park, a marketing subsidiary, and a manufacturing base in Qidong, Jiangsu, and has built a commercialization network covering 31 provinces, autonomous regions, and municipalities with a marketing team of over 950 people.
- 2026
Licenses in a potential global first-in-class ADC; furmonertinib adjuvant treatment marketing application accepted by NMPA
- 2023
艾弗沙® first-line indication enters NRDL
- 2022
艾弗沙® first-line indication approved for EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive locally advanced or metastatic NSCLC; receives 2021 Drug Innovation Jishi Award
- 2021
NMPA approves 艾弗沙® (furmonertinib mesylate), Allist's second Class 1 new drug; 艾弗沙® enters NRDL; overseas exclusive licensing agreement with ArriVent; technology transfer agreement with Fudan University for PGAM1 inhibitor KH3
- 2020
Partnership with Belgium's OCTIMET Oncology; listed on SSE STAR Market on December 2 (stock code 688578)
- 2019
A/A+ round financing completed; shareholding reform completed as Shanghai Allist Pharmaceuticals Co., Ltd.; Shanghai Allist Marketing Planning Co., Ltd. founded; furmonertinib included in NMPA priority review list; headquarters R&D base broke ground
- 2016
NMPA approves clinical trial application for furmonertinib; high-tech enterprise re-certification passed
- 2013
Allisartan transferred to Shenzhen Salubris Pharmaceuticals
- 2012
NMPA approves allisartan, China's first Class 1 antihypertensive sartan drug
- 2010
Jiangsu Allist formally founded with registered capital of RMB 240 million; allisartan included in National Major New Drug Innovation Program
Products and positioning
Innovation-driven oncology biopharmaceutical company developing first-in-class and best-in-class drugs with independent IP, focused on unmet clinical needs in oncology.
艾弗沙® (furmonertinib mesylate tablets)
Third-generation EGFR inhibitor; approved for EGFR mutation-positive NSCLC; first-line indication approved 2022, entered NRDL 2023
艾瑞凯® (glecirasib citrate tablets)
Oral KRAS G12C inhibitor
普吉华® (pralsetinib capsules)
Allist holds exclusive promotion rights in mainland China
Pipeline: RET inhibitor, KRAS G12C inhibitor, KRAS G12D inhibitor, SOS1 inhibitor, fourth-generation EGFR inhibitor
Preclinical programs targeting NSCLC, colorectal cancer, pancreatic cancer, and C797S resistance mutations
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/allist · Editorial policy · How profiles are compiled